Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

J&J Remicade Hepatotoxicity Warning Is Subject Of “Dear Doctor” Letter

  • News

Executive Summary

Johnson & Johnson is alerting prescribers to a new hepatotoxicity warning in Remicade labeling via a "Dear Doctor" letter

You may also be interested in...



J&J Remicade Labeling Adds TNF-Inhibitor Malignancy Warning

Centocor is revising Remicade (infliximab) labeling to include a malignancy warning similar to that of other TNF-inhibitors

J&J’s Remicade Adds Hematologic, Neurologic Warnings To Label

Johnson & Johnson's TNF-inhibitor Remicade has added warnings for hematologic and neurologic events to its label

Enbrel Cleared For Ankylosing Spondylitis; Heart Failure Precaution Added

Amgen/Wyeth is awaiting approval for two additional Enbrel indications following FDA clearance of the TNF-inhibitor for ankylosing spondylitis July 24

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS045187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By